Marinus Pharma (MRNS) Tops Q1 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022 4:04 PM EDTZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 TrustTSC trial in tuberous sclerosis complex; topline data anticipated first quarter 2024 Patient dosing underway for Phase 1 trial of ganaxolone second generation formulation; topline data on track for mid-2022 readout Continue to strengthen cash position with Oaktree Capital drawdown and expectation to monetize priority review voucher Marinus to host conference call today at 4:05 p.m.... More
